Bispecific Antibody Therapy Education

This educational series provides a comprehensive overview of bispecific T-cell engager therapies, including mechanisms of action, treatment pathways, and the recognition and management of key toxicities such as cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS).

Bispecific antibodies represent an evolving class of therapies that activate the immune system to recognize and eliminate cancer cells, offering additional treatment options for patients with complex or relapsed disease.

Who Should Enroll?

This course is intended for Mayo Clinic Employees only who are directly involved in the delivery, management, and support of bispecific antibody therapies. 

While the core content is consistent across all courses, each version has been tailored to reflect the workflows, responsibilities, and clinical considerations unique to different care settings and roles.

To ensure the most relevant and applicable learning experience, please select the course that best matches your area of expertise or practice environment.

Choose Your Learning Path

Select the course that aligns with your role to access tailored content designed to support your practice and improve patient outcomes.